2.1 Psychosocial Disorders, Substance Use & Environmental Exposures

Perinatal Mental Health Disorders & Psychotropic Safety

Perinatal mental health conditions represent one of the most common medical complications of pregnancy and the postpartum period, affecting approximately 15% to 20% of perinatal individuals. Unrecognized and untreated maternal psychiatric illness is directly linked to adverse obstetric and neonatal outcomes, including impaired prenatal care engagement, severe nutritional deficiencies, increased rates of self-medication, preterm birth, low birth weight, and impaired maternal-infant bonding. Inpatient obstetric nurses must possess advanced diagnostic awareness, understand psychotropic safety profiles, and execute timely suicide and psychosis risk assessments.

Perinatal Depression & Anxiety Disorders

• Epidemiology & Impact: Depression and anxiety can manifest de novo during pregnancy or represent exacerbations of pre-existing disorders. Maternal stress hormones (cortisol and catecholamines) cross the placenta, altering fetal hypothalamic-pituitary-adrenal (HPA) axis development and increasing risks for intrauterine growth restriction and preterm delivery.
• Validated Clinical Screening Instruments:
  • Edinburgh Postnatal Depression Scale (EPDS): A 10-item self-report instrument validated for antepartum and postpartum use. A score ≥10 indicates possible depression warranting clinical follow-up; a score ≥13 indicates high risk of major depressive disorder. Item 10 specifically assesses self-harm and suicidal ideation; any score above 0 on Item 10 mandates an immediate, same-day, in-person clinical safety and suicide risk assessment before the patient is discharged.
  • Patient Health Questionnaire-9 (PHQ-9): Evaluates DSM-5 depressive criteria over the prior 2 weeks, with scores ≥10 indicating moderate-to-severe depression.
  • Generalized Anxiety Disorder 7-item (GAD-7): Rapidly screens for generalized anxiety, panic disorder, and severe situational anxiety.
• Selective Serotonin Reuptake Inhibitors (SSRIs) & Psychotropic Safety:
  • First-line pharmacotherapy for moderate to severe perinatal depression includes SSRIs such as sertraline, citalopram, and escitalopram. Sertraline is frequently favored due to minimal placental transfer and low concentrations in breast milk.
  • Paroxetine Consideration: Historically linked to a small potential increased risk of congenital cardiovascular malformations (ventricular and atrial septal defects) when taken during early first-trimester organogenesis; routine new initiation during pregnancy is generally avoided.
  • Discontinuation Warning: Patients stabilized on an antidepressant should never abruptly discontinue medication upon discovering pregnancy. Abrupt cessation carries a >50% to 70% relapse rate. The physiological and behavioral risks of untreated maternal depression generally outweigh the small potential pharmacologic risks.
  • Neonatal Poor Adaptation Syndrome (NPAS): Approximately 20% to 30% of neonates exposed to SSRIs or SNRIs late in the third trimester exhibit transient, self-limiting symptoms (mild jitteriness, weak cry, transient tachypnea, mild hypoglycemia, hypertonia, or feeding difficulty). Symptoms typically appear within 24 to 48 hours after birth and resolve completely within 48 to 72 hours with supportive nursing measures (skin-to-skin contact, swaddling, frequent low-volume feedings, quiet environment).

Bipolar Disorder & Postpartum Psychosis

• Bipolar Disorder Management: Carries a 25% to 50% risk of acute postpartum recurrence. Lithium remains an essential mood stabilizer for severe bipolar disorder. While historically associated with Ebstein anomaly (downward displacement of the tricuspid valve leaflets), the absolute risk is low (~1 in 1,000 to 1 in 2,000 exposed pregnancies compared to 1 in 20,000 baseline). Physiological increases in renal blood flow and glomerular filtration rate (GFR) during pregnancy accelerate lithium clearance, requiring serum lithium monitoring every 2 to 4 weeks during pregnancy and weekly near term. Therapeutic serum levels must be maintained between 0.6 and 1.0 mEq/L. Strict maternal hydration during labor prevents acute lithium toxicity (tremors, ataxia, slurred speech, arrhythmias).
• Major Teratogen Warnings: Valproic acid (Depakote) and carbamazepine are potent teratogens. Valproate exposure causes major congenital malformations, including neural tube defects (lumbar meningomyelocele in 1% to 2%), craniofacial clefts, cardiovascular anomalies, and long-term neurocognitive/IQ deficits. Valproate is strictly contraindicated in pregnancy unless all other therapies have failed.
• Postpartum Psychosis: A severe psychiatric emergency occurring in 1 to 2 per 1,000 deliveries, with the highest incidence among patients with bipolar disorder or a prior history of postpartum psychosis. Onset is abrupt, typically manifesting within the first 48 hours to 2 weeks postpartum. Hallmark manifestations include auditory/visual hallucinations, delusions (often involving the infant being defective, evil, or doomed), delirium, gross confusion, and extreme mood lability. Immediate psychiatric hospitalization is mandatory; the infant must be physically separated from unsupervised contact with the mother due to high risks of infanticide (~4%) and maternal suicide (~5%).

---

Substance Use Disorders (SUD) in Pregnancy

Substance use disorders must be managed through a chronic disease framework utilizing trauma-informed, compassionate, and non-stigmatizing clinical care.

Universal Screening Protocols

ACOG, SMFM, and AWHONN recommend universal verbal screening for substance use at the first prenatal encounter using validated questionnaires rather than unconsented routine biological drug testing:

┌────────────────────────────────────────────────────────────────────────┐
│               VALIDATED PERINATAL SUBSTANCE SCREENING                  │
├───────────────────┬────────────────────────────────────────────────────┤
│ Screening Tool    │ Clinical Focus & Structure                         │
├───────────────────┼────────────────────────────────────────────────────┤
│ 4Ps Plus          │ Parents, Partner, Past, Present substance use      │
│ CRAFFT            │ Validated for adolescents and young adults <21 yrs │
│ NIDA Quick Screen │ Multi-substance risk categorization tool           │
│ SBIRT Framework   │ Screening, Brief Intervention, Referral to Therapy │
└───────────────────┴────────────────────────────────────────────────────┘

Biological Drug Testing Rules: Biological drug testing (urine/blood toxicology) requires informed maternal consent according to hospital policy and applicable state legal statutes. A positive toxicology screen indicates prior chemical exposure, not functional impairment or substance use disorder, and always requires confirmatory testing by gas chromatography-mass spectrometry (GC-MS).

Opioid Use Disorder (OUD) & Medications for Opioid Use Disorder (MOUD)

• Gold-Standard Therapy: Medication-Assisted Treatment (MAT) / Medications for Opioid Use Disorder (MOUD) utilizing either methadone (full mu-opioid receptor agonist) or buprenorphine (partial mu-opioid receptor agonist). Buprenorphine monoproduct is commonly utilized, though combination formulations (buprenorphine/naloxone) are also supported in clinical practice.
• Why Medically Supervised Detoxification is Contraindicated: Acute opioid detoxification during pregnancy is strongly discouraged. It carries a catastrophic relapse rate (>80% to 90%) and precipitates severe maternal-fetal autonomic instability, leading to fetal hypoxemia, meconium aspiration, preterm labor, acute placental abruption, and intrauterine fetal demise.
• Intrapartum Analgesia Management in Opioid-Dependent Patients:
  • Continue Maintenance Therapy: The patient's daily baseline methadone or buprenorphine dose must be administered on schedule throughout labor. Maintenance doses satisfy physical receptor dependence but do not provide labor analgesia.
  • CRITICAL CONTRAINDICATION: Mixed opioid agonist-antagonists (butorphanol [Stadol] and nalbuphine [Nubain]) must NEVER be administered. These agents displace full/partial agonists from mu-opioid receptors, instantly precipitating severe acute maternal-fetal opioid withdrawal and acute fetal heart rate decelerations.
  • Analgesia Modalities: Early neuraxial labor analgesia (lumbar epidural) is the gold standard. When systemic analgesia is required, additional full opioid agonists (e.g., fentanyl, morphine, hydromorphone) are titrated at higher dosages under continuous maternal-fetal monitoring to overcome receptor tolerance.
• Neonatal Opioid Withdrawal Syndrome (NOWS) & The Eat, Sleep, Console (ESC) Model:
  • Infants exposed in utero are assessed for central nervous system hyperirritability, gastrointestinal dysfunction, and autonomic instability.
  • The modern evidence-based Eat, Sleep, Console (ESC) approach emphasizes non-pharmacologic first-line care: maternal rooming-in, uninterrupted skin-to-skin contact, low-stimulation environments (dim lights, minimal noise), swaddling, and on-demand breastfeeding (unless contraindicated by maternal HIV infection, active illicit substance use, or active untreated tuberculosis).

Sympathomimetic Stimulants: Cocaine & Methamphetamines

• Mechanism of Action: Cocaine and methamphetamines block the reuptake of catecholamines (epinephrine, norepinephrine, dopamine) at presynaptic terminals, resulting in intense, sustained maternal-fetal vasoconstriction and acute tachycardia.
• Perinatal Complications:
  • Placental Abruption (Abruptio Placentae): Severe uterine arterial vasospasm and acute spikes in maternal blood pressure cause decidual ischemia, focal necrosis, and retroplacental hematoma formation.
  • Fetal Growth Restriction (FGR) & Microcephaly: Chronic uteroplacental hypoperfusion restricts oxygen and nutrient transport.
  • Preterm Labor & PPROM: Direct sympathomimetic stimulation increases myometrial contractility.
  • Fetal Vascular Disruptions: In utero cerebral infarction, necrotizing enterocolitis, limb reduction defects, and intestinal atresia.
• Intrapartum Nursing Care: Close surveillance for acute hypertensive crisis, hyperthermia, agitation, and cardiac arrhythmias. Pure beta-blockers must be avoided to prevent catastrophic paradoxical hypertension from unopposed alpha-adrenergic stimulation; combined alpha/beta blockers (e.g., labetalol) or direct vasodilators are preferred.

Tobacco, Nicotine & Cannabis

• Tobacco & Nicotine Vaping: Carbon monoxide binds maternal and fetal hemoglobin to form carboxyhemoglobin, shifting the oxygen-hemoglobin dissociation curve to the left and reducing fetal tissue oxygen delivery. Nicotine causes potent fetoplacental vasoconstriction. Tobacco use is a major dose-dependent risk factor for fetal growth restriction, placenta previa, placental abruption, PPROM, sudden infant death syndrome (SIDS), and orofacial clefts. Nursing intervention applies the 5 A's (Ask, Advise, Assess, Assist, Arrange).
• Cannabis: Delta-9-tetrahydrocannabinol (THC) readily crosses the placenta and concentrates in fetal brain tissue, binding CB1 cannabinoid receptors. Maternal cannabis use is associated with low birth weight, altered neonatal behavioral responses, and childhood deficits in executive functioning and attention. ACOG advises complete cessation during pregnancy and lactation.

---

Intimate Partner Violence (IPV) in Pregnancy

Intimate partner violence affects approximately 1 in 6 pregnant individuals and is a leading contributor to maternal trauma, homicide, and severe obstetric morbidity.

                   [ UNIVERSAL IPV SCREENING & ACTION WORKFLOW ]
                                         │
                  ┌──────────────────────┴──────────────────────┐
                  ▼                                             ▼
      [ 1. Complete Privacy ]                        [ 2. Validated Inquiry ]
      Isolate patient from partner,                  Use direct, empathetic questions:
      family, or visitors >2 years old.              "Within the past year, has anyone hit,
      Use routine specimen collection as pretext.    slapped, kicked, or physically hurt you?"
                  │                                             │
                  └──────────────────────┬──────────────────────┘
                                         │
                                         ▼
                            [ 3. Patient Discloses IPV ]
                                         │
         ┌───────────────────────────────┼───────────────────────────────┐
         ▼                               ▼                               ▼
 [ Empathetic Validation ]       [ Lethality Assessment ]        [ Safety Planning ]
 "You are not alone."            Evaluate threats, weapons,      Identify safe contacts, pack
 "This is not your fault."       strangulation history, and      emergency documents, provide
 "We have resources to help."    escalation during pregnancy.    National Hotline: 800-799-SAFE

Clinical Red Flags & Mandatory Reporting Rules

• Physical Signs: Injuries to breasts, abdomen, inner thighs, or buttocks; bruises in multiple stages of healing; facial or cervical contusions; injuries inconsistent with reported mechanisms.
• Behavioral Indicators: Late or missed prenatal visits, unexplained chronic pelvic pain, partner refusing to leave the patient's bedside, partner insisting on answering questions on the patient's behalf.
• Legal Reporting Considerations: In most jurisdictions, mandatory reporting for competent adult IPV victims does not occur without the patient's explicit consent, unless injuries involve firearms, stab wounds, or severe felony assaults. Unauthorized reporting can trigger lethal retaliatory violence from the perpetrator. (In contrast, suspected child abuse or vulnerable adult abuse mandates immediate statutory reporting).

---

Teratogens & Environmental Exposures